Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Baxter International (BAX) in Your Portfolio

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Medtronic (MDT) Expands AI-Driven Care With New Partnership

Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?

Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Here's Why You Should Retain McKesson (MCK) Stock for Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Masimo's (MASI) ORi Favored by Study for PaO2 Information

Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.

Thermo Fisher (TMO) Launches New Solutions for Clinical Labs

Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.

Why You Should Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

McKesson (MCK) Announces Availability of FDA-Approved Drug

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.

Illumina (ILMN) Expands Globally Despite Macroeconomic Woes

The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.

Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY

Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.

AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome

AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.

BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS

BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.